|Bid||68.11 x 800|
|Ask||70.21 x 3000|
|Day's range||68.45 - 69.53|
|52-week range||26.49 - 77.49|
|Beta (5Y monthly)||1.40|
|PE ratio (TTM)||16.51|
|Earnings date||27 Jan 2021 - 01 Feb 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||86.62|
Hologic to Showcase Products Across Breast Cancer Screening, Biopsy, Surgery and Treatment at Virtual RSNA2020
After a detailed study of Driehaus' strategy, AAII concluded that it mainly focuses on strong earnings growth rates and impressive prospects to pick potential outperformers.
Hologic (HOLX) could produce exceptional returns because of its solid growth attributes.